[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568354":3},{"organization":4,"outcomesModule":7,"designInfo":72,"detailedDescription":85,"studyPopulation":77,"armGroups":86,"interventions":133,"overallOfficials":77,"centralContacts":155,"locations":161,"responsibleParty":214,"collaborators":77,"id":216,"slug":77,"hasResults":217,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":77,"eligibilityCriteria":221,"healthyVolunteers":222,"sex":223,"minAge":224,"maxAge":77,"enrollmentInfo":225,"targetDuration":77,"studyType":228,"phases":229,"briefSummary":232,"conditions":233,"keywords":77,"overallStatus":164,"whyStopped":77,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},{"fullName":5,"class":6},"SK Bioscience Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":41,"otherOutcomes":60},[9,13,16,18,21,24,27,31,35,37,39],{"measure":10,"description":11,"timeFrame":12},"Percentage of participants experiencing any immediate reactions","For all cohort","30 minutes (2 hours for the sentinel participants in stage 1) post each vaccination",{"measure":14,"description":11,"timeFrame":15},"Percentage of participants reporting any solicited local Adverse Event (AE)","during the 7 days following each study vaccination",{"measure":17,"description":11,"timeFrame":15},"Percentage of participants reporting any solicited systemic Adverse Event (AE)",{"measure":19,"description":11,"timeFrame":20},"Percentage of participants experiencing any unsolicited Adverse Event (AE)","during the 28 days following each study vaccination",{"measure":22,"description":11,"timeFrame":23},"Percentage of participants with any Medically Attended Adverse Event (MAAE)","until 6 months following the last study vaccination",{"measure":25,"description":11,"timeFrame":26},"Percentage of participants experiencing any Adverse Event of Special Interest (AESI)s, AEs leading to study withdrawal and Serious Adverse Event (SAE)s during the entire study period","up to 12 months for stage 1 and up to 24 months for stage 2",{"measure":28,"description":29,"timeFrame":30},"Seroprotection rate for both the respective and cross Japanese encephalitis virus (JEV) strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers at each time point","For stage 2","At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.",{"measure":32,"description":33,"timeFrame":34},"Seroresponse rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers, from baseline to each subsequent time point","For Stage 2","At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination",{"measure":36,"description":29,"timeFrame":30},"Geometric Mean Titer (GMT) of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) measured by a live-virus neutralization assay (PRNT) at each time point",{"measure":38,"description":33,"timeFrame":34},"Geometric mean fold rise of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2,Beijing-1 strain), measured by a live-virus neutralization assay(PRNT), from each pre-vaccination to each subsequent timepoint",{"measure":40,"description":33,"timeFrame":30},"Geometric mean fold reduction of neutralizing antibody against both respective and cross JEV strains of each vaccine (SA-14-14-2,Beijing-1 strain), measured by live-virus neutralization assay (PRNT) from persistence baseline to each subsequent timepoint",[42,46,49,51,54,57],{"measure":43,"description":44,"timeFrame":45},"Seroprotection rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers at each time point","For Stage 1","At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination",{"measure":47,"description":48,"timeFrame":45},"Seroresponse rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers, from baseline to each subsequent time point.","For stage 1",{"measure":50,"description":48,"timeFrame":45},"GMT of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) measured by a live-virus neutralization assay (PRNT) at each time point",{"measure":52,"description":48,"timeFrame":53},"Geometric mean fold rise of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2,Beijing-1 strain), measured by live-virus neutralization assay(PRNT), from each pre-vaccination to each subsequent timepoint","At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination.",{"measure":55,"description":56,"timeFrame":53},"Geometric mean fold reduction of neutralizing antibody against both respective and cross JEV strains of each vaccine (SA-14-14-2,Beijing-1 strain),measured by live-virus neutralization assay(PRNT) from persistence baseline to each subsequent timepoint","For Stage1",{"measure":58,"description":11,"timeFrame":59},"Cell-mediated response for cytokines expressed by Cluster of Differentiation 4+ Cluster of Differentiation 8+ T cells (Interferon-γ, Tumor Necrosis Factor-α, measured by Fluorescence-Activated Cell Sorting-Intracellular Cytokine Staining assay.","At baseline, 4 weeks following the 1st study vaccination, and at 4 weeks and 6 months following the 2nd study vaccination",[61,65,67,69],{"measure":62,"description":63,"timeFrame":64},"Seroprotection rate for the heterologous JEV strains of each vaccine (including, but not limited to K95A07, Bennett, JKT 6468, Sangju-v1 strains) in live-virus neutralizing antibody titers at each timepoint.","will be evaluated exclusively in a subset of approximately 20% of participants in stage 1, 10% of participants in stage 2","At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination. and 24 months following the 2nd study vaccination (for stage2 only)",{"measure":66,"description":63,"timeFrame":64},"GMT of neutralizing antibody against the heterologous JEV strains of each vaccine (including, but not limited to K95A07, Bennett, JKT 6468, Sangju-v1 strains) measured by a live-virus neutralization assay (PRNT) at each timepoint",{"measure":68,"description":63,"timeFrame":64},"Seroresponse rate for the heterologous JEV strains of each vaccine (including, but not limited to K95A07, Bennett, JKT 6468, Sangju-v1 strains) in live-virus neutralizing antibody titers, from baseline to each subsequent time point",{"measure":70,"description":71,"timeFrame":64},"Geometric mean fold rise of neutralizing antibody against the heterologous JEV strains of each vaccine (including,but not limited to K95A07, Bennett, JKT 6468, Sangju-v1) measured by the PRNT assay, from each pre-vaccination to each subsequent time point","will be evaluated exclusively in a subset of approximately 20% of participants in stage 1, 10% of participants in stage 2.",{"allocation":73,"interventionModel":74,"interventionModelDescription":75,"primaryPurpose":76,"observationalModel":77,"timePerspective":77,"maskingInfo":78},"RANDOMIZED","SEQUENTIAL","Stage 1: sequential, Stage 2 : parallel","PREVENTION",null,{"masking":79,"maskingDescription":77,"whoMasked":80},"QUADRUPLE",[81,82,83,84],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","The purpose of this study is to assess the safety, reactogenicity and immunogenicity of SK Japanese Encephalitis mRNA vaccines (GBP560) in healthy adults.",[87,93,98,102,106,110,114,120,126,130],{"label":88,"type":89,"description":90,"interventionNames":91},"Test group 1-1 (GBP560-A)","EXPERIMENTAL","Low dose level(3µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.",[92],"Biological: GBP560-A",{"label":94,"type":89,"description":95,"interventionNames":96},"Test group 1-2 (GBP560-B)","Low dose level (3µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.",[97],"Biological: GBP560-B",{"label":99,"type":89,"description":100,"interventionNames":101},"Test group1-3 (GBP560-A)","Mid dose level (15µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.",[92],{"label":103,"type":89,"description":104,"interventionNames":105},"Test group1-4 (GBP560-B)","Mid dose level (15µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.",[97],{"label":107,"type":89,"description":108,"interventionNames":109},"Test group1-5 (GBP560-A)","High dose level (50µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.",[92],{"label":111,"type":89,"description":112,"interventionNames":113},"Test group1-6 (GBP560-B)","High dose level (50µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.",[97],{"label":115,"type":116,"description":117,"interventionNames":118},"Control group1 (IXIARO®)","ACTIVE_COMPARATOR","Participants will receive 2 doses of one of the active comparators (IXIARO®, 6 Antigen Unit, corresponding to a potency of ≤ 460 ng ED) at 4-week intervals, respectively in Stage 1 and Stage 2.",[119],"Biological: IXIARO",{"label":121,"type":116,"description":122,"interventionNames":123},"Control group2 (IMOJEV®)","Participants will receive 1 dose of placebo saline and 1 dose of another active comparator (IMOJEV®, 4.0 - 5.8 log PFU) at 4-week intervals, respectively in Stage 1 and Stage 2.",[124,125],"Biological: IMOJEV","Biological: Normal Saline (Placebo)",{"label":127,"type":89,"description":128,"interventionNames":129},"Test group 2-1 (GBP560-A or B)","Participants will receive 2 intramuscular injections of the test vaccines in stage 2.\n\n1st will be on Visit 2 and 2nd will be on Visit 5, in line with the selected dose regimen in stage 1.",[92,97],{"label":131,"type":89,"description":128,"interventionNames":132},"Test group 2-2 (GBP560-A or B)",[92,97],[134,139,143,147,151],{"type":135,"name":136,"description":137,"armGroupLabels":138,"otherNames":77},"BIOLOGICAL","GBP560-A","injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.\n\nLow dose: 3μg Mid dose: 15μg High dose: 50μg",[88,127,131,99,107],{"type":135,"name":140,"description":141,"armGroupLabels":142,"otherNames":77},"GBP560-B","injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.\n\nLow dose: 3μg Mid dose: 15μg High dose: 50μg",[94,127,131,103,111],{"type":135,"name":144,"description":145,"armGroupLabels":146,"otherNames":77},"IXIARO","injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2",[115],{"type":135,"name":148,"description":149,"armGroupLabels":150,"otherNames":77},"IMOJEV","injection volume of 0.5mL on V5 (29day) in stage1 and stage2",[121],{"type":135,"name":152,"description":153,"armGroupLabels":154,"otherNames":77},"Normal Saline (Placebo)","injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)",[121],[156],{"name":157,"role":158,"phone":159,"phoneExt":77,"email":160},"Sejun Oh","CONTACT","82-2-2008-2200","sejunoh@sk.com",[162,182,194],{"facility":163,"status":164,"city":165,"state":77,"zip":77,"country":166,"countryCode":167,"cosmosGeoPoint":168,"geoPoint":173,"contacts":174},"Nucleus Network - Brisbane (Q Pharm)","RECRUITING","Brisbane","Australia","AU",{"type":169,"coordinates":170},"Point",[171,172],153.02809,-27.46794,{"lat":172,"lon":171},[175,179],{"name":176,"role":158,"phone":177,"phoneExt":77,"email":178},"Gabrielle Robb","+61-7-3707-2784","g.robb@nucleusnetwork.com.au",{"name":180,"role":181,"phone":77,"phoneExt":77,"email":77},"Michael Wong","PRINCIPAL_INVESTIGATOR",{"facility":183,"status":164,"city":184,"state":77,"zip":77,"country":166,"countryCode":167,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Nucleus Network - Melbourne","Melbourne",{"type":169,"coordinates":186},[187,188],144.96332,-37.814,{"lat":188,"lon":187},[191,192],{"name":176,"role":158,"phone":177,"phoneExt":77,"email":178},{"name":193,"role":181,"phone":77,"phoneExt":77,"email":77},"Christina Chang",{"facility":195,"status":196,"city":197,"state":198,"zip":199,"country":200,"countryCode":201,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"New Zealand Clinical Research","NOT_YET_RECRUITING","Christchurch","Central City","8011","New Zealand","NZ",{"type":169,"coordinates":203},[204,205],172.63333,-43.53333,{"lat":205,"lon":204},[208,212],{"name":209,"role":158,"phone":210,"phoneExt":77,"email":211},"Kayla Malate","+64 9 373 3474 ext. 7165","kayla.malate@nzcr.co.nz",{"name":213,"role":181,"phone":77,"phoneExt":77,"email":77},"Cory Sellwood",{"type":215,"investigatorFullName":77,"investigatorTitle":77,"investigatorAffiliation":77,"oldNameTitle":77,"oldOrganization":77},"SPONSOR","100568354",false,"NCT06680128","A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","A 2-Stage, Phase I\u002FII, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)","Inclusion Criteria:\n\n\\[Age\\]\n\n1. For Stage 1, participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.\n\n   For Stage 2, participant must be 18 years of age and older, at the time of signing the informed consent.\n\n   \\[Type of Participant and Disease Characteristics\\]\n2. Participants who are healthy as determined by medical evaluation including medical history, vital signs, physical examination, clinical laboratory tests and medical judgement of the investigator.\n3. Participants who are willing and able to attend all scheduled visits and comply with all study procedures.\n4. Body mass index (BMI) within the range of 18.5-29.9 kg\u002Fm2 (inclusive) at screening\n\n   \\[Sex and Contraceptive\u002FBarrier Requirements\\]\n5. All participants must agree to be heterosexually inactive or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last study vaccination (Visit 9) (See Appendix 10.4 for detailed contraceptive methods).\n6. Female participants with a negative urine or serum pregnancy test at screening.\n\n   \\* Female participants who are surgically sterile (e.g., having undergone a full hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal with amenorrhea for at least 12 months are not subject to a pregnancy test.\n\n   \\[Informed Consent\\]\n7. Participants who are capable of giving signed informed consent as described in Appendix 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol before initiation of any trial-specific procedures.\n\nExclusion Criteria:\n\n\\[Medical Conditions\\]\n\n1. Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile illness (tympanic temperature \\>38°C), or acute illness within 24 hours prior to the 1st study vaccination. Prospective participants with these conditions cannot be included until 24 hours after resolution.\n2. History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease.\n3. Any positive test results for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at screening.\n4. History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion.\n5. History of hypersensitivity and severe allergic reaction (e.g., anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study intervention.\n6. History of myocarditis, pericarditis or myopericarditis (including the screening 12-lead ECG results from Stage 1 participants), as assessed by the investigator, indicating probable or possible myocarditis, pericarditis, or myopericarditis, or demonstrating clinically significant abnormalities that could affect participant safety or the interpretation of study findings.\n7. History of JEV infection\u002Fother flaviviruses infection (e.g., Dengue, West Nile, Zika, St. Louis Encephalitis, Yellow fever).\n8. History of malignancy within 1 year prior to the 1st study vaccination (with the exception of malignancy with minimal risk of recurrence at the discretion of the investigator).\n9. Significant unstable chronic or acute illness that, in the opinion of the investigator, might pose a health risk to the participant if enrolled, or could interfere with the protocol-specified activities, or interpretation of study results.\n\n   \\* The AESIs as outlined in Section 8.1.4 should be considered for evaluating the participant\n10. Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or psychiatric conditions).\n11. Female participants who are pregnant or breastfeeding.\n12. (Only for Stage 1) Current smoker or a recent smoking history within 12 weeks prior to screening. Occasional smoker who smokes up to 10 cigarettes per month may be allowed to participate at the investigator's discretion.\n\n    \\[Prior\u002FConcomitant medication\\]\n13. Receipt of JEV vaccination\u002Fother flaviviruses vaccination in the past.\n14. Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned receipt of any vaccine from enrollment through 4 weeks after the last study vaccination (Visit 8), except for inactivated influenza vaccination, which may be received at least 2 weeks prior to the 1st study vaccination.\n15. Receipt of immunoglobulins and\u002For any blood or blood-derived products within 12 weeks prior to the 1st study vaccination.\n16. Receipt of immunosuppressive therapy, such as any use of anti-cancer chemotherapy or radiation therapy; or systemic corticosteroid therapy (≥10 mg prednisone\u002Fday or equivalent) within 12 weeks prior to the 1st study vaccination. The use of inhaled, topical, or nasal glucocorticoid will be permitted.\n\n    \\[Prior\u002FConcurrent Clinical Study Experience\\]\n17. Participation in another clinical study and receipt of study intervention within 4 weeks prior to the 1st study vaccination, or concurrent, planned participation in another clinical study with study intervention during this study period.\n\n    \\[Other Exclusions\\]\n18. Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.\n19. Donation of ≥ 450mL (milliliter) of blood product within 4 weeks prior to screening, or planned donation of blood product from enrollment through 12 weeks after the last study vaccination (Visit 9).",true,"ALL","18 Years",{"count":226,"type":227},402,"ESTIMATED","INTERVENTIONAL",[230,231],"PHASE1","PHASE2","This is a 2-Stage, Phase I\u002FII Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)",[234],"Japanese Encephalitis Virus Disease","2025-12-16",{"date":237,"type":238},"2025-12-23","ACTUAL",{"date":240,"type":238},"2025-02-24",{"date":242,"type":227},"2028-03-19",{"name":5,"class":6},3]